Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Compass Therapeutics LLC is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, reflecting a focused prosecution effort. The involvement of 1 distinct art unit indicates that the subject matter is contained within a specific pharmaceutical or biological classification. This streamlined approach minimizes the need to coordinate across different USPTO departments.
SANG, HONG is the busiest examiner for this portfolio, with 1 busiest examiner pending action. Given that the total volume is 1 pending office action, SANG, HONG is the sole examiner currently reviewing the company's active applications. This relationship between the action and the examiner centralizes the prosecution process. The 1 busiest examiner pending action represents the entirety of the company's current workload in the Biotechnology & Pharmaceuticals sector.
The data shows that the company's current patent activity is concentrated under 1 distinct examiner and 1 distinct art unit. This provides a clear and direct path for prosecution, as there are no other pending actions to manage. Practitioners can focus their strategy on the specific examination style of the assigned examiner. With only 1 pending office action, the immediate success of the portfolio depends on the resolution of this matter within the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANG, HONG | 1 | 55.0% | +62.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365745 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | SANG, HONG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365745 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | SANG, HONG | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18365745 | AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | SANG, HONG | 1646 | §101§102§103§112Other | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial